Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340887 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KMT2ARAB9A | |
| SCHEMBL28908606 | 0.78 | TNF (0.60) | ALDH1A1MAPTTNFPDE4APDE4B | |
| SCHEMBL7296263 | 0.77 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL524126 | 0.77 | ALDH1A1 (0.67) | ALDH1A1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL15785094 | 0.77 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL23089859 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL21834869 | 0.75 | CA12 (0.47) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL14393320 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KMT2ARAB9A | |
| SCHEMBL14928649 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KMT2ARAB9A | |
| SCHEMBL7296253 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2548872-B1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2548872-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
| CN-102884053-A | Cyclopropanecarboxylic acid derivatives | DAIICHI SANKYO CO LTD | 2013-01-16 | — | — | CN | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| WO-2011115065-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | 第一三共株式会社 (JP) | 2011-09-22 | — | — | WO | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | ALDH1A1 2914/4885MAPT 4784/4885TNF 4155/4885 |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | ALDH1A1 2914/4885MAPT 4784/4885TNF 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.